4.7 Article

Extending human healthspan and longevity: a symposium report

期刊

ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
卷 1507, 期 1, 页码 70-83

出版社

WILEY
DOI: 10.1111/nyas.14681

关键词

biological aging; healthspan; hallmarks of aging; geroscience; longevity

资金

  1. NIH/NIA [AG021904, AG038072, AG031782, K23AG051148, R01 AG061155]
  2. JPB Foundation
  3. Rainwater Charitable Foundation
  4. American Federation for Aging Research
  5. NIH [R01 AG069698, RF1 AG061834, R01 AG068405, P30 AG068345, P01 AG055369]
  6. Nathan Shock Centers of Excellence in the Basic Biology of Aging [P30 AG038072]
  7. Paul F. Glenn Center for the Biology of Human Aging
  8. [R01 AG063543]
  9. [R01 AG063543-03S1]
  10. [P01 AG043376]
  11. [U19 AG056278]

向作者/读者索取更多资源

Geroscience posits that aging is malleable and by targeting the hallmarks of biological aging, age-related diseases can be alleviated and longevity extended. Experts have made significant advancements in understanding the mechanisms underlying biological aging and identified ways to target aging pathways. Proof-of-concept studies and early-stage clinical trials are underway to assess the feasibility of drug evaluation in geroscience.
For many years, it was believed that the aging process was inevitable and that age-related diseases could not be prevented or reversed. The geroscience hypothesis, however, posits that aging is, in fact, malleable and, by targeting the hallmarks of biological aging, it is indeed possible to alleviate age-related diseases and dysfunction and extend longevity. This field of geroscience thus aims to prevent the development of multiple disorders with age, thereby extending healthspan, with the reduction of morbidity toward the end of life. Experts in the field have made remarkable advancements in understanding the mechanisms underlying biological aging and identified ways to target aging pathways using both novel agents and repurposed therapies. While geroscience researchers currently face significant barriers in bringing therapies through clinical development, proof-of-concept studies, as well as early-stage clinical trials, are underway to assess the feasibility of drug evaluation and lay a regulatory foundation for future FDA approvals in the future.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据